APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide CXO

Peptide CXO covers outsourced research, process development and manufacturing for peptide programmes, from research material and analytical work to clinical and commercial supply.

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peptide CXO Market Outlook and Growth Opportunities 2026

23 December 2025194 pages

Choose your research edition.

Industry ResearchPeptide CXO Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide CXO Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Peptide CXO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide CXO Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide CXO Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Peptide CXO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peptide CXO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide CXO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide CXO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peptide CXO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peptide CXO market include Chinese Peptide Company, WuXi AppTec, Shenzhen JYMed Technology, ReaLi Tide Biological Technology, Jiangsu Sinopep-Allsino Biopharmaceutical, LONZA, Asymchem, GL Biochem and Chengdu Shengnuo Biotechnology, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Peptide CXO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide CXO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide CXO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Peptide CXO market.

Peptide CXO Segment by Company

Chinese Peptide Company

WuXi AppTec

Shenzhen JYMed Technology

ReaLi Tide Biological Technology

Jiangsu Sinopep-Allsino Biopharmaceutical

LONZA

Asymchem

GL Biochem

Chengdu Shengnuo Biotechnology

AmbioPharm

Polypeptide

Pepscan

JPT Peptide

Bicycle

Bachem

Peptide CXO Segment by Type

CRO

CMO/CDMO

Peptide CXO Segment by Application

Pharmaceutical Companies

Biotech Companies and Research Institutions

Peptide CXO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Peptide CXO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Peptide CXO key companies, revenue, market share, and recent developments.

3. To split the Peptide CXO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Peptide CXO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide CXO significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide CXO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide CXO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide CXO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide CXO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide CXO industry.

Chapter 3: Detailed analysis of Peptide CXO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Peptide CXO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Peptide CXO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide CXO Industry Trends Table 2. Peptide CXO Industry Drivers Table 3. Peptide CXO Industry Opportunities and Challenges Table 4. Peptide CXO Industry Restraints Table 5. Global Peptide CXO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide CXO Revenue Share by Company (2021-2026) Table 7. Global Peptide CXO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Peptide CXO Key Company Manufacturing Base & Headquarters Table 9. Global Peptide CXO Company, Product Type & Application Table 10. Global Peptide CXO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Peptide CXO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of CRO Table 15. Significant Companies of CMO/CDMO Table 16. Global Peptide CXO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Peptide CXO Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Peptide CXO Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Peptide CXO Sales Value Share by Type (2021-2026) Table 20. Global Peptide CXO Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Pharmaceutical Companies Table 22. Significant Companies of Biotech Companies and Research Institutions Table 23. Global Peptide CXO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Peptide CXO Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Peptide CXO Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Peptide CXO Sales Value Share by Application (2021-2026) Table 27. Global Peptide CXO Sales Value Share by Application (2027-2032) Table 28. Global Peptide CXO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Peptide CXO Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Peptide CXO Sales Value Share by Region (2021-2026) Table 31. Global Peptide CXO Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Peptide CXO Sales Value Share by Region (2027-2032) Table 33. Global Peptide CXO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Peptide CXO Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Peptide CXO Sales Value Market Share by Country (2021-2026) Table 36. Global Peptide CXO Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Peptide CXO Sales Value Market Share by Country (2027-2032) Table 38. Chinese Peptide Company Company Information Table 39. Chinese Peptide Company Business Overview Table 40. Chinese Peptide Company Peptide CXO Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Chinese Peptide Company Peptide CXO Product Portfolio Table 42. Chinese Peptide Company Recent Development Table 43. WuXi AppTec Company Information Table 44. WuXi AppTec Business Overview Table 45. WuXi AppTec Peptide CXO Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. WuXi AppTec Peptide CXO Product Portfolio Table 47. WuXi AppTec Recent Development Table 48. Shenzhen JYMed Technology Company Information Table 49. Shenzhen JYMed Technology Business Overview Table 50. Shenzhen JYMed Technology Peptide CXO Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Shenzhen JYMed Technology Peptide CXO Product Portfolio Table 52. Shenzhen JYMed Technology Recent Development Table 53. ReaLi Tide Biological Technology Company Information Table 54. ReaLi Tide Biological Technology Business Overview Table 55. ReaLi Tide Biological Technology Peptide CXO Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. ReaLi Tide Biological Technology Peptide CXO Product Portfolio Table 57. ReaLi Tide Biological Technology Recent Development Table 58. Jiangsu Sinopep-Allsino Biopharmaceutical Company Information Table 59. Jiangsu Sinopep-Allsino Biopharmaceutical Business Overview Table 60. Jiangsu Sinopep-Allsino Biopharmaceutical Peptide CXO Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Jiangsu Sinopep-Allsino Biopharmaceutical Peptide CXO Product Portfolio Table 62. Jiangsu Sinopep-Allsino Biopharmaceutical Recent Development Table 63. LONZA Company Information Table 64. LONZA Business Overview Table 65. LONZA Peptide CXO Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. LONZA Peptide CXO Product Portfolio Table 67. LONZA Recent Development Table 68. Asymchem Company Information Table 69. Asymchem Business Overview Table 70. Asymchem Peptide CXO Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Asymchem Peptide CXO Product Portfolio Table 72. Asymchem Recent Development Table 73. GL Biochem Company Information Table 74. GL Biochem Business Overview Table 75. GL Biochem Peptide CXO Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. GL Biochem Peptide CXO Product Portfolio Table 77. GL Biochem Recent Development Table 78. Chengdu Shengnuo Biotechnology Company Information Table 79. Chengdu Shengnuo Biotechnology Business Overview Table 80. Chengdu Shengnuo Biotechnology Peptide CXO Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Chengdu Shengnuo Biotechnology Peptide CXO Product Portfolio Table 82. Chengdu Shengnuo Biotechnology Recent Development Table 83. AmbioPharm Company Information Table 84. AmbioPharm Business Overview Table 85. AmbioPharm Peptide CXO Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. AmbioPharm Peptide CXO Product Portfolio Table 87. AmbioPharm Recent Development Table 88. Polypeptide Company Information Table 89. Polypeptide Business Overview Table 90. Polypeptide Peptide CXO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Polypeptide Peptide CXO Product Portfolio Table 92. Polypeptide Recent Development Table 93. Pepscan Company Information Table 94. Pepscan Business Overview Table 95. Pepscan Peptide CXO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Pepscan Peptide CXO Product Portfolio Table 97. Pepscan Recent Development Table 98. JPT Peptide Company Information Table 99. JPT Peptide Business Overview Table 100. JPT Peptide Peptide CXO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. JPT Peptide Peptide CXO Product Portfolio Table 102. JPT Peptide Recent Development Table 103. Bicycle Company Information Table 104. Bicycle Business Overview Table 105. Bicycle Peptide CXO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Bicycle Peptide CXO Product Portfolio Table 107. Bicycle Recent Development Table 108. Bachem Company Information Table 109. Bachem Business Overview Table 110. Bachem Peptide CXO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Bachem Peptide CXO Product Portfolio Table 112. Bachem Recent Development Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Peptide CXO Product Image Figure 2. Global Peptide CXO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide CXO Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide CXO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. CRO Image Figure 8. CMO/CDMO Image Figure 9. Global Peptide CXO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Peptide CXO Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Peptide CXO Sales Value Share by Type (2021-2032) Figure 12. Pharmaceutical Companies Image Figure 13. Biotech Companies and Research Institutions Image Figure 14. Global Peptide CXO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Peptide CXO Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Peptide CXO Sales Value Share by Application (2021-2032) Figure 17. Global Peptide CXO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Peptide CXO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Peptide CXO Sales Value (2021-2032) & (US$ Million) Figure 20. North America Peptide CXO Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Peptide CXO Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Peptide CXO Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Peptide CXO Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Peptide CXO Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Peptide CXO Sales Value (2021-2032) & (US$ Million) Figure 26. South America Peptide CXO Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Peptide CXO Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Peptide CXO Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Peptide CXO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Peptide CXO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Peptide CXO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • CRO
  • CMO/CDMO
Applications
  • Pharmaceutical Companies
  • Biotech Companies and Research Institutions
Companies covered
  • Chinese Peptide Company
  • WuXi AppTec
  • Shenzhen JYMed Technology
  • ReaLi Tide Biological Technology
  • Jiangsu Sinopep-Allsino Biopharmaceutical
  • LONZA
  • Asymchem
  • GL Biochem
  • Chengdu Shengnuo Biotechnology
  • AmbioPharm
  • Polypeptide
  • Pepscan
  • JPT Peptide
  • Bicycle
  • Bachem

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peptide CXO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peptide CXO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Peptide CXO Market Dynamics
  1. 2.1 Peptide CXO Industry Trends
  2. 2.2 Peptide CXO Industry Drivers
  3. 2.3 Peptide CXO Industry Opportunities and Challenges
  4. 2.4 Peptide CXO Industry Restraints
3 Peptide CXO Market by Company
  1. 3.1 Global Peptide CXO Company Revenue Ranking in 2025
  2. 3.2 Global Peptide CXO Revenue by Company (2021-2026)
  3. 3.3 Global Peptide CXO Company Ranking (2024-2026)
  4. 3.4 Global Peptide CXO Company Manufacturing Base and Headquarters
  5. 3.5 Global Peptide CXO Company Product Type and Application
  6. 3.6 Global Peptide CXO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Peptide CXO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Peptide CXO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Peptide CXO Market by Type
  1. 4.1 Peptide CXO Type Introduction
  2. 4.1.1 CRO
  3. 4.1.2 CMO/CDMO
  4. 4.2 Global Peptide CXO Sales Value by Type
  5. 4.2.1 Global Peptide CXO Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Peptide CXO Sales Value by Type (2021-2032)
  7. 4.2.3 Global Peptide CXO Sales Value Share by Type (2021-2032)
5 Peptide CXO Market by Application
  1. 5.1 Peptide CXO Application Introduction
  2. 5.1.1 Pharmaceutical Companies
  3. 5.1.2 Biotech Companies and Research Institutions
  4. 5.2 Global Peptide CXO Sales Value by Application
  5. 5.2.1 Global Peptide CXO Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Peptide CXO Sales Value by Application (2021-2032)
  7. 5.2.3 Global Peptide CXO Sales Value Share by Application (2021-2032)
6 Peptide CXO Regional Value Analysis
  1. 6.1 Global Peptide CXO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide CXO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Peptide CXO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Peptide CXO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peptide CXO Sales Value (2021-2032)
  7. 6.3.2 North America Peptide CXO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Peptide CXO Sales Value (2021-2032)
  10. 6.4.2 Europe Peptide CXO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Peptide CXO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Peptide CXO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Peptide CXO Sales Value (2021-2032)
  16. 6.6.2 South America Peptide CXO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Peptide CXO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Peptide CXO Sales Value Share by Country, 2025 VS 2032
7 Peptide CXO Country-level Value Analysis
  1. 7.1 Global Peptide CXO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide CXO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Peptide CXO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Peptide CXO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Peptide CXO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Peptide CXO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Peptide CXO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Peptide CXO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Peptide CXO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Peptide CXO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Peptide CXO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Peptide CXO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Peptide CXO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Peptide CXO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Peptide CXO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Peptide CXO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Peptide CXO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Peptide CXO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Peptide CXO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Peptide CXO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Peptide CXO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Peptide CXO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Peptide CXO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Peptide CXO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Peptide CXO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Peptide CXO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Peptide CXO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Peptide CXO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Peptide CXO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Peptide CXO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Peptide CXO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Peptide CXO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Peptide CXO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Peptide CXO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Peptide CXO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Peptide CXO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Peptide CXO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Peptide CXO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Peptide CXO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Peptide CXO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Peptide CXO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Peptide CXO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Peptide CXO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Peptide CXO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Peptide CXO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Peptide CXO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Peptide CXO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Peptide CXO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Peptide CXO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Peptide CXO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Peptide CXO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Peptide CXO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Peptide CXO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Peptide CXO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Peptide CXO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Peptide CXO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Peptide CXO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Peptide CXO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Peptide CXO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Peptide CXO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Peptide CXO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Peptide CXO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Peptide CXO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Peptide CXO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Peptide CXO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Peptide CXO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Peptide CXO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Peptide CXO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Peptide CXO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Peptide CXO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Peptide CXO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Peptide CXO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Peptide CXO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Peptide CXO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Peptide CXO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Peptide CXO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Peptide CXO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Peptide CXO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Peptide CXO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Peptide CXO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Peptide CXO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Peptide CXO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Peptide CXO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Peptide CXO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Peptide CXO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Peptide CXO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Peptide CXO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Peptide CXO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chinese Peptide Company
  2. 8.1.1 Chinese Peptide Company Company Information
  3. 8.1.2 Chinese Peptide Company Business Overview
  4. 8.1.3 Chinese Peptide Company Peptide CXO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chinese Peptide Company Peptide CXO Product Portfolio
  6. 8.1.5 Chinese Peptide Company Recent Developments
  7. 8.2 WuXi AppTec
  8. 8.2.1 WuXi AppTec Company Information
  9. 8.2.2 WuXi AppTec Business Overview
  10. 8.2.3 WuXi AppTec Peptide CXO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 WuXi AppTec Peptide CXO Product Portfolio
  12. 8.2.5 WuXi AppTec Recent Developments
  13. 8.3 Shenzhen JYMed Technology
  14. 8.3.1 Shenzhen JYMed Technology Company Information
  15. 8.3.2 Shenzhen JYMed Technology Business Overview
  16. 8.3.3 Shenzhen JYMed Technology Peptide CXO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shenzhen JYMed Technology Peptide CXO Product Portfolio
  18. 8.3.5 Shenzhen JYMed Technology Recent Developments
  19. 8.4 ReaLi Tide Biological Technology
  20. 8.4.1 ReaLi Tide Biological Technology Company Information
  21. 8.4.2 ReaLi Tide Biological Technology Business Overview
  22. 8.4.3 ReaLi Tide Biological Technology Peptide CXO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ReaLi Tide Biological Technology Peptide CXO Product Portfolio
  24. 8.4.5 ReaLi Tide Biological Technology Recent Developments
  25. 8.5 Jiangsu Sinopep-Allsino Biopharmaceutical
  26. 8.5.1 Jiangsu Sinopep-Allsino Biopharmaceutical Company Information
  27. 8.5.2 Jiangsu Sinopep-Allsino Biopharmaceutical Business Overview
  28. 8.5.3 Jiangsu Sinopep-Allsino Biopharmaceutical Peptide CXO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Jiangsu Sinopep-Allsino Biopharmaceutical Peptide CXO Product Portfolio
  30. 8.5.5 Jiangsu Sinopep-Allsino Biopharmaceutical Recent Developments
  31. 8.6 LONZA
  32. 8.6.1 LONZA Company Information
  33. 8.6.2 LONZA Business Overview
  34. 8.6.3 LONZA Peptide CXO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 LONZA Peptide CXO Product Portfolio
  36. 8.6.5 LONZA Recent Developments
  37. 8.7 Asymchem
  38. 8.7.1 Asymchem Company Information
  39. 8.7.2 Asymchem Business Overview
  40. 8.7.3 Asymchem Peptide CXO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Asymchem Peptide CXO Product Portfolio
  42. 8.7.5 Asymchem Recent Developments
  43. 8.8 GL Biochem
  44. 8.8.1 GL Biochem Company Information
  45. 8.8.2 GL Biochem Business Overview
  46. 8.8.3 GL Biochem Peptide CXO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GL Biochem Peptide CXO Product Portfolio
  48. 8.8.5 GL Biochem Recent Developments
  49. 8.9 Chengdu Shengnuo Biotechnology
  50. 8.9.1 Chengdu Shengnuo Biotechnology Company Information
  51. 8.9.2 Chengdu Shengnuo Biotechnology Business Overview
  52. 8.9.3 Chengdu Shengnuo Biotechnology Peptide CXO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Chengdu Shengnuo Biotechnology Peptide CXO Product Portfolio
  54. 8.9.5 Chengdu Shengnuo Biotechnology Recent Developments
  55. 8.10 AmbioPharm
  56. 8.10.1 AmbioPharm Company Information
  57. 8.10.2 AmbioPharm Business Overview
  58. 8.10.3 AmbioPharm Peptide CXO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AmbioPharm Peptide CXO Product Portfolio
  60. 8.10.5 AmbioPharm Recent Developments
  61. 8.11 Polypeptide
  62. 8.11.1 Polypeptide Company Information
  63. 8.11.2 Polypeptide Business Overview
  64. 8.11.3 Polypeptide Peptide CXO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Polypeptide Peptide CXO Product Portfolio
  66. 8.11.5 Polypeptide Recent Developments
  67. 8.12 Pepscan
  68. 8.12.1 Pepscan Company Information
  69. 8.12.2 Pepscan Business Overview
  70. 8.12.3 Pepscan Peptide CXO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Pepscan Peptide CXO Product Portfolio
  72. 8.12.5 Pepscan Recent Developments
  73. 8.13 JPT Peptide
  74. 8.13.1 JPT Peptide Company Information
  75. 8.13.2 JPT Peptide Business Overview
  76. 8.13.3 JPT Peptide Peptide CXO Revenue and Gross Margin (2021-2026)
  77. 8.13.4 JPT Peptide Peptide CXO Product Portfolio
  78. 8.13.5 JPT Peptide Recent Developments
  79. 8.14 Bicycle
  80. 8.14.1 Bicycle Company Information
  81. 8.14.2 Bicycle Business Overview
  82. 8.14.3 Bicycle Peptide CXO Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bicycle Peptide CXO Product Portfolio
  84. 8.14.5 Bicycle Recent Developments
  85. 8.15 Bachem
  86. 8.15.1 Bachem Company Information
  87. 8.15.2 Bachem Business Overview
  88. 8.15.3 Bachem Peptide CXO Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Bachem Peptide CXO Product Portfolio
  90. 8.15.5 Bachem Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst